# PRIOR AUTHORIZATION CRITERIA

BRAND NAME\* (generic)

DALIRESP (roflumilast)

Status: CVS Caremark Criteria Type: Initial Prior Authorization

Ref # 646-A

#### FDA-APPROVED INDICATIONS

Daliresp is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Limitations of Use

Daliresp is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

Daliresp 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose.

#### **COVERAGE CRITERIA**

The requested drug will be covered with prior authorization when the following criteria are met:

The requested drug is being prescribed to reduce the risk of chronic obstructive pulmonary disease (COPD)
 exacerbations in a patient with severe COPD associated with chronic bronchitis and a history of exacerbations

### **RATIONALE**

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Daliresp is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Daliresp is not a bronchodilator and is not indicated for the relief of acute bronchospasm. Daliresp 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose.

### **REFERENCES**

- 1. Daliresp [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2019.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. http://online.lexi.com/. Accessed November 2020.
- 3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http://www.micromedexsolutions.com/. Accessed November 2020.

Written by: UM Development (RP)

Date Written: 04/2011

Revised: (RP) 06/2011 (revised question #2, added question #3), 02/2012; 10/2012 (extended duration); (RP) 02/2013, (TM) 11/2013;

(RP) 11/2014, 11/2015 (no clinical changes), 11/2016, 11/2017 (no clinical changes); (KC) 11/2018 (no clinical changes), 04/2019

(changed DOA to 12 months); (RP) 03/2020 (no clinical changes), (TM) 11/2020 (no clinical changes)


Reviewed: Medical Affairs (KP) 04/2011, 06/2011, 02/2012, 10/2012; (LS) 02/2013, (DC) 11/2013; (LMS) 11/2014; (ME) 11/2016; (GAD)

04/2019; (CHART) 03/26/2020, 12/03/2020

External Review: 06/2011, 06/2012, 06/2013, 04/2014, 02/2015, 02/2016, 02/2017, 02/2018, 02/2019, 06/2019, 06/2020, 02/2021

Daliresp PA 646-A 11-2020

©2020 CVS Caremark. All rights reserved.





<sup>\*</sup> Drugs that are listed in the target drug box include both brand and generic and all dosage forms and strengths unless otherwise stated. OTC products are not included unless otherwise stated.

## **CRITERIA FOR APPROVAL**

1 Is the requested drug being prescribed to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in a patient with severe COPD associated with chronic bronchitis and a history of exacerbations?

Yes

No

Mapping Instructions			
	Yes	No	DENIAL REASONS – DO NOT USE FOR MEDICARE PART D
1.	Approve, 12 months	Deny	You do not meet the requirements of your plan. Your plan covers this drug when you meet all of these conditions:  - You have severe chronic obstructive pulmonary disease (COPD)  - Your condition is associated with chronic bronchitis and a history of exacerbations  Your request has been denied based on the information we have.  [Short Description: No approvable diagnosis]

Daliresp PA 646-A 11-2020

pharmaceutical manufacturers not affiliated with CVS Caremark.

©2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written